NKGN (NKGen Biotech) Goodwill : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. NKGen Biotech's goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil.

NKGen Biotech Goodwill Historical Data

The historical data trend for NKGen Biotech's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Goodwill Chart

NKGen Biotech Annual Data

Trend

Dec21

Dec22

Dec23

Goodwill

NKGen Biotech Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Goodwill	Get a 7-Day Free Trial					-	-	-	-	-

NKGen Biotech Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.

NKGen Biotech (OTCPK:NKGN) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

NKGen Biotech's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill-to-Asset (A: Dec. 2023 )	=	Goodwill	/	Total Assets
	=	0	/	16.481
	=

NKGen Biotech's Goodwill-to-Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Goodwill-to-Asset (Q: Sep. 2024 )	=	Goodwill	/	Total Assets
	=	0	/	14.995
	=

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.

NKGen Biotech Goodwill Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (OTCPK:NKGN) » Definitions » Goodwill

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.